Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2009 Results
Date:2/10/2010

ables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its products and other factors described under the caption "Risk Factors That May Affect Future Results" in the Company's Quarterly Report on Form 10-Q for the period ending September 30, 2009.  Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.  New factors emerge from time to time and it is not possible for the Company to predict which will arise.  In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2008 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.  The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including APIs, advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals.  The Company currently employs approximately 850 people worldwide.  For more information, please visit

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports First Quarter 2009 Results
7. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... 2015 goals, other key objectives, and financial guidance.  ... today at 4:30 p.m. EST to review the ... To participate in today,s call by telephone, please ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 On behalf ... its affiliated companies, Wilentz, Goldman & Spitzer, P.A. ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript’s trade secrets, and that it improperly ... court entered an order denying motions for judgment notwithstanding ...
(Date:2/26/2015)... Already well respected for accuracy, HEIDENHAIN now ... Length Gauge offerings with new variants of its successful ... HEIDENHAIN’s pencil probe-style SPECTO length gauge series now offers ... 1Vpp, 12mm stroke length variants of the SPECTO series ... variant with a weak spring, 0.4N of gauging force, ...
(Date:2/26/2015)... Regis Technologies announced new potent ... drug substances. , Regis Technologies is proud to announce ... Compound Suite (PCS) for 2015. , Regis is a ... facility in Morton Grove, Illinois. The PCS addition will ... up to about one kilogram per batch. , ...
Breaking Biology Technology:Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Regis Extends cGMP Services to Oncology Market 2
... -- Four Oak Ridge National Laboratory researchers are among ... as part of the Department of Energy,s new Early ... under the American Recovery and Reinvestment Act by the ... researchers during the crucial early career years, when many ...
... , , SCOTTSDALE, Ariz. , ... of the delivery of modern-day cancer care in community oncology ... costs of administering chemotherapy and providing related infusion room services ... services provided such as treatment planning, care coordination, and follow-up ...
... Fourth Quarter and Year End 2009 Financial Results , VANCOUVER , ... ANP) will host a conference call discussing its financial results for the ... Thursday, March 4, 2010 at 9:00 AM ET ( ... March 4, 2010 is as follows: , North America ...
Cached Biology Technology:4 ORNL researchers selected for Recovery Act early career funds 24 ORNL researchers selected for Recovery Act early career funds 3Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer 2Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer 3Study: Medicare Covers Only Half the Cost of Administering Chemotherapy to Seniors with Cancer 4Angiotech Pharmaceuticals Announces Conference Call and Webcast 2
(Date:1/22/2015)...  Today, FreeWavz ( www.FreeWavz.com ), the developer of ... Fundable, https://www.fundable.com/freewavz . FreeWavz will be expanding ... meet customer demand. Logo - ... Invented by Dr. Eric ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
(Date:1/22/2015)... Issued by Small Cap IR. In 2011, Nilson Report,s annual ... merchants on the leading payment cards rose to $135.3 billion ... prepaid cards reached 6.54 billion.  Eight million credit card users ... 2012, and credit and debit card fraud resulted in $11.27 ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... neuroscientists at Oregon Health & Science University Doernbecher Children,s ... strength MRI to reveal tiny white matter injuries in ... Early, accurate identification of these lesions in the ... enable physicians to inform families sooner of the potential ...
... of 22 young European scientists selected for excellence in ... scientists join a growing network of more than 300 ... have the potential to be tomorrow,s life science leaders," ... the Young Investigator Programme. "They are already active contributors ...
... and physics aims to understand the cell and how ... very complicated. LMU biophysicist Professor Erwin Frey, who is ... Initiative Munich" (NIM) is working with his group on ... professor for statistical and biological physics and his team, ...
Cached Biology News:First use of high-field MRI in developing brain reveals previously undetectable injuries 222 young researchers join the 2011 EMBO Young Investigator Program 2Attention! End of traffic jam! 2
Peptide-affinity Purified Polyclonal Antibody to ICEBERG Peptide with sequence EEDPQLASKMGLH, from C Terminus of the protein sequence according to NP_067546...
EDG-6 Lysate Source: Cell Lysate Application: Western Blotting Control Form: IgG...
3T3 cells (RSV-transformed) Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: